Sweden

Dela

Om oss

Maxim Pharmaceuticals utvecklar nya metoder för behandling av cancer och infektionssjukdomar.

Välj datumintervall -
Taggar ( valda)

MAXIM PHARMACEUTICALS ANNOUNCES RESTRUCTURING PLAN TO SUPPORT COMMERCIALIZATION AND DEVELOPMENT EFFORTS

MAXIM PHARMACEUTICALS ANNOUNCES RESTRUCTURING PLAN TO SUPPORT COMMERCIALIZATION AND DEVELOPMENT EFFORTS CONFERENCE CALL SCHEDULED FOR OCTOBER 19, 2004, 7:00 AM PACIFIC TIME SAN DIEGO, October 18, 2004 - Maxim Pharmaceuticals (Nasdaq: MAXM) (SSE: MAXM) today announced that it is implementing a restructuring plan to reduce its cash burn rate. The plan is intended to ensure that Maxim has sufficient financial resources to properly focus on efforts to pursue regulatory submissions seeking approval of Ceplene® to treat acute myeloid leukemia (AML) patients in complete remission, and other

MAXIM PHARMACEUTICALS REPORTS PUBLICATION OF 36-MONTH MALIGNANT MELANOMA SURVIVAL DATA FOR CEPLENE(TM)

MAXIM PHARMACEUTICALS REPORTS PUBLICATION OF 36-MONTH MALIGNANT MELANOMA SURVIVAL DATA FOR CEPLENE(TM) Publication in JOURNAL OF CANCER IMMUNOLOGY AND IMMUNOTHERAPY SAN DIEGO - June 4, 2004 -- Maxim Pharmaceuticals, Inc. (Nasdaq:MAXM) (SSE: MAXM) today announced that the 36-month patient follow-up data from the M01 Phase 3 study of Ceplene(TM) (histamine dihydrochloride) as a combination therapy to treat advanced metastatic melanoma has been published electronically in an article by Hellstrand et al, for the June issue of the Journal of Cancer Immunology and Immunotherapy. The 36-month

MAXIM PHARMACEUTICALS ANNOUNCES FISCAL 2004 FIRST QUARTER FINANCIAL RESULTS

MAXIM PHARMACEUTICALS ANNOUNCES FISCAL 2004 FIRST QUARTER FINANCIAL RESULTS SAN DIEGO, Calif., February 3, 2004 -- Maxim Pharmaceuticals, Inc. (Nasdaq NM: MAXM, SSE: MAXM) today announced results for the quarter ended December 31, 2003, the first quarter of the Company's 2004 fiscal year. The net loss applicable to common stock for the first quarter totaled $9.9 million, or $0.35 per share, compared to a loss applicable to common stock of $9.3 million, or $0.40 per share, for the same period of the prior year. The current quarter increase in net loss primarily resulted from the Company's

Det finns inga träffar som matchar nuvarande filter
Det finns inga fler träffar som matchar nuvarande filter
Tillbaka till sidans topp